At Ending Age-Related Diseases 2020, Dr. Eric Leire of Genflow Biosciences discussed his company, explaining what Genflow does and how it is funded. The company is intervening directly in the biology of aging, affecting SIRT6, which, like other sirtuins, is a known regulator of aging. The company intends to develop its SIRT6 plasmid as an epigenomic therapy that will affect downstream hallmarks of aging, potentially providing a broad-based solution to multiple age-related diseases.
2023 was a busy and productive year for Genflow Biosciences Plc (“Genflow) marked by significant advancements in our mission to pioneer novel therapeutics for a
We are thrilled to be named “a firm to watch” by The Guardian. Undoubtedly, the success of our NASH studies this past year and the
Health Tech World has announced its Top 50 health tech innovators of 2022
Headquarters
Genflow Biosciences plc
6 Heddon Street
London
W1B 4BT
United Kingdom
Research and Development
Genflow Biosciences SRL
Biopark Gosselies
Rue Clément Ader, 10
B-6041 Charleroi
Belgium
US office address
Genflow Biosciences Inc
1050 Connecticut Avenue
Suite 500
Washington DC
20036, USA